Literature DB >> 1908441

Functional characterization of tumor-infiltrating lymphocytes, lymph-node lymphocytes and peripheral-blood lymphocytes from patients with breast cancer.

A Rubbert1, B Manger, N Lang, J R Kalden, E Platzer.   

Abstract

Mononuclear cell infiltration is frequently seen within human solid tumors. Effector cells within the tumor site usually fail to exhibit cytotoxic or natural killer activity when freshly isolated; however, they develop potent and sometimes specific cytotoxicity after expansion in IL2. Thus, local tumor environment may influence lymphocyte function. In our study, we disaggregated human breast-cancer and lymph-node tissue to obtain lymphocyte-enriched cell fractions. Besides phenotypic analysis, functional characterization with regard to proliferation and cytokine production of tumor-infiltrating lymphocytes (TIL), peripheral-blood lymphocytes (PBL) and lymph-node lymphocytes (LNL) was the aim of our study. TIL showed an enrichment of CD8+ cells with a corresponding decrease in CD4+ cells in comparison with PBL and LNL. In response to PHA, TIL showed decreased 3H-thymidine uptake, but TIL were significantly stimulated by rhIL2. TIL produced low levels of IL2, TNF and IFN gamma upon mitogen/phorbol ester stimulation, while PBL produce high levels of TNF and IFN gamma but low levels of IL2. Under the same experimental conditions, LNL produce high levels of TNF and IL2 but low levels of IFN gamma. Mitogen-mediated TNF secretion was increased after addition of autologous tumor cells in TIL and LNL, whereas IFN gamma secretion tended to be suppressed. Our results indicate different patterns of activities of TIL, LNL and PBL from breast-cancer patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1908441     DOI: 10.1002/ijc.2910490106

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

Review 1.  Immunotherapeutic approaches for the treatment of breast cancer.

Authors:  K L Knutson; K Schiffman; K Rinn; M L Disis
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

2.  In vitro analysis of cancer prevention by a mycobacterial antigen complex and of cancer-promoted inhibition of immune reactions.

Authors:  H Maes; C Cocito
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

3.  Lymphocytes infiltrating colorectal cancer have low proliferative capacity but can secrete normal levels of interferon gamma.

Authors:  W J Bateman; I Donnellan; I A Fraser; L S Wong; A G Morris
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

4.  Lymphocyte populations in human lymph nodes. Alterations in CD4+ CD25+ T regulatory cell phenotype and T-cell receptor Vbeta repertoire.

Authors:  Alessandra Battaglia; Gabriella Ferrandina; Alessia Buzzonetti; Paolo Malinconico; Francesco Legge; Vanda Salutari; Giovanni Scambia; Andrea Fattorossi
Journal:  Immunology       Date:  2003-11       Impact factor: 7.397

5.  CD4+ T lymphocytes infiltrating human breast cancer recognise autologous tumor in an MHC-class-II restricted fashion.

Authors:  R Dadmarz; M K Sgagias; S A Rosenberg; D J Schwartzentruber
Journal:  Cancer Immunol Immunother       Date:  1995-01       Impact factor: 6.968

6.  Lymphokine-activated killer cell function of peripheral blood mononuclear cells, spleen cells and regional lymph node cells in gastric cancer patients.

Authors:  N Karimine; S Arinaga; H Inoue; S Nanbara; H Ueo; T Akiyoshi
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

7.  Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization.

Authors:  L Boldrini; A Calcinai; E Samaritani; F Pistolesi; A Mussi; M Lucchi; C A Angeletti; F Basolo; G Fontanini
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

8.  Expression of tumour necrosis factor alpha and its receptors in carcinoma of the breast.

Authors:  L Pusztai; L M Clover; K Cooper; P M Starkey; C E Lewis; J O McGee
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.